These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23656803)

  • 1. Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?
    Glurich I; Berg RL; Burmester JK
    Clin Med Res; 2013 Jun; 11(2):73-9. PubMed ID: 23656803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.
    Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E
    Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.
    Voora D; Koboldt DC; King CR; Lenzini PA; Eby CS; Porche-Sorbet R; Deych E; Crankshaw M; Milligan PE; McLeod HL; Patel SR; Cavallari LH; Ridker PM; Grice GR; Miller RD; Gage BF
    Clin Pharmacol Ther; 2010 Apr; 87(4):445-51. PubMed ID: 20200517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
    Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
    Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
    Shahin MH; Khalifa SI; Gong Y; Hammad LN; Sallam MT; El Shafey M; Ali SS; Mohamed ME; Langaee T; Johnson JA
    Pharmacogenet Genomics; 2011 Mar; 21(3):130-5. PubMed ID: 21228733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.
    Scott SA; Patel M; Martis S; Lubitz SA; van der Zee S; Yoo C; Edelmann L; Halperin JL; Desnick RJ
    Pharmacogenomics; 2012 Feb; 13(3):297-307. PubMed ID: 22188360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
    Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F
    Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients.
    Xu Q; Zhang S; Wu C; Xiong Y; Niu J; Li F; Zhu J; Shen L; Zhu B; Xing Q; He L; Chen L; Li M; Li H; Ge J; Qin S
    J Cardiovasc Pharmacol; 2021 Jul; 78(1):e105-e111. PubMed ID: 33958549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients.
    Sandanaraj E; Lal S; Cheung YB; Xiang X; Kong MC; Lee LH; Ooi LL; Chowbay B
    Drug Metab Pharmacokinet; 2009; 24(4):365-75. PubMed ID: 19745563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.
    Hernandez W; Gamazon ER; Aquino-Michaels K; Smithberger E; O'Brien TJ; Harralson AF; Tuck M; Barbour A; Cavallari LH; Perera MA
    J Thromb Haemost; 2017 Apr; 15(4):735-743. PubMed ID: 28135054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.
    Mushiroda T; Ohnishi Y; Saito S; Takahashi A; Kikuchi Y; Saito S; Shimomura H; Wanibuchi Y; Suzuki T; Kamatani N; Nakamura Y
    J Hum Genet; 2006; 51(3):249-253. PubMed ID: 16432637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians.
    Shahin MH; Cavallari LH; Perera MA; Khalifa SI; Misher A; Langaee T; Patel S; Perry K; Meltzer DO; McLeod HL; Johnson JA
    Thromb Haemost; 2013 Jun; 109(6):1045-50. PubMed ID: 23571513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CALU polymorphism A29809G affects calumenin availability involving vascular calcification.
    Jover E; Marín F; Quintana M; Pérez-Andreu J; Hurtado JA; Rodríguez C; Martínez-González J; González-Conejero R; Valdés M; Hernández-Romero D
    J Mol Cell Cardiol; 2015 May; 82():218-27. PubMed ID: 25823396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.